Cargando…

CO139 Use of Remdesivir Among Hospitalized Patients with Severe COVID-19: Analysis of Electronic Health Records from Trinetx COVID-19 Network

Detalles Bibliográficos
Autores principales:	Wolde, F, Gressler, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232773/ http://dx.doi.org/10.1016/j.jval.2022.04.234

Ejemplares similares

Intellectual and developmental disability and COVID-19 case-fatality trends: TriNetX analysis
por: Turk, Margaret A., et al.
Publicado: (2020)

Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020)

Remdesivir for COVID-19
Publicado: (2020)

Remdesivir and COVID-19
por: Glaus, Matthew J, et al.
Publicado: (2020)

Remdesivir and COVID-19
por: Wang, Lei-Yun, et al.
Publicado: (2020)

Remdesivir and COVID-19
por: Dennis, Alicia
Publicado: (2020)

Remdesivir and COVID-19
por: Edwards, Jessie K, et al.
Publicado: (2020)

Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir’s Value
por: Anderson, Michaela R., et al.
Publicado: (2020)

Compassionate Use of Remdesivir for Patients with Severe Covid-19
por: Grein, Jonathan, et al.
Publicado: (2020)

Remdesivir cost effective for severe COVID-19 in China
Publicado: (2021)

Length of remdesivir treatment in patients with severe COVID-19
por: Ippolito, Mariachiara, et al.
Publicado: (2021)

Is It Time to Revisit Remdesivir Use for Severe COVID-19?
por: Taggarsi, Dipali Anand
Publicado: (2022)

Remdesivir treatment for patients with moderate to severe COVID-19
por: HASANOĞLU, İmran, et al.
Publicado: (2022)

The risk of methicillin-resistant Staphylococcus aureus infection following COVID-19 and influenza: A retrospective cohort study from the TriNetX network
por: Tsai, Ya-Wen, et al.
Publicado: (2023)

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
por: Kalil, Andre C., et al.
Publicado: (2020)

The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19
por: Whittington, Melanie D., et al.
Publicado: (2022)

Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients
por: Coelho, Luís, et al.
Publicado: (2023)

Remdesivir for patients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2021)

Safety and effectiveness of COVID-19 vaccines in patients with IgA nephropathy: a retrospective cohort study from the TriNetX global collaborative networks
por: Chen, Cheng-Hsu, et al.
Publicado: (2023)

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
por: Goldman, Jason D., et al.
Publicado: (2020)

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
por: Gottlieb, Robert L., et al.
Publicado: (2021)

Remdesivir in moderate to severe COVID-19: A matter of time?
por: Bonazzetti, Cecilia, et al.
Publicado: (2021)

Severe COVID-19 Pneumonia in an Unvaccinated Female Treated With Remdesivir
por: Ortega, Kaylee, et al.
Publicado: (2022)

Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis
por: Geffin, Ryan, et al.
Publicado: (2023)

Remdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19)
por: Zerbit, Jeremie, et al.
Publicado: (2022)

Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: A retrospective cohort study from the TriNetX US collaborative networks
por: Wang, Weijie, et al.
Publicado: (2022)

Real-life use of remdesivir in hospitalized patients with COVID-19
por: Garcia-Vidal, Carolina, et al.
Publicado: (2021)

Remdesivir modifies interferon response in hospitalized COVID-19 patients
por: Murphy, Sarah L., et al.
Publicado: (2022)

Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
por: Rosas, Ivan O., et al.
Publicado: (2021)

Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience
por: Moriello, Nicola Schiano, et al.
Publicado: (2023)

Corrigendum to “Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks”
por: Wang, Weijie, et al.
Publicado: (2023)

Remdesivir and COVID-19 – Authors' reply
por: Wang, Yeming, et al.
Publicado: (2020)

To Determine the Efficacy of Remdesivir in Covid-19
por: Hameed, A., et al.
Publicado: (2022)

Remdesivir senkt COVID-19-Hospitalisierung
por: Dovjak, Peter, et al.
Publicado: (2022)

Remdesivir: From Ebola to COVID-19
por: Santoro, M. Gabriella, et al.
Publicado: (2021)

The place for remdesivir in COVID-19 treatment
por: Young, Barnaby, et al.
Publicado: (2021)

Remdesivir: A Review in COVID-19
por: Blair, Hannah A.
Publicado: (2023)

Effects on LOS may not justify cost of remdesivir for severe COVID-19
Publicado: (2021)

A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19
por: Ngo, Dallis Q., et al.
Publicado: (2022)

Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia
por: Petrakis, Vasilis, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pqv02dpcdbl8p0ve75hhhaedt8